Global Epoetin Beta Erythropoietin Market Size, Share and Trends Analysis Report, By Type (Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta, and Others), By Application (Anemia, Kidney Disorders, and Other), Forecast (2022-2028)

The global epoetin beta erythropoietin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The primary factor driving the growth of the erythropoietin market is the increase in the prevalence of anemic conditions caused by end-stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART). As a result, an increase in the number of chemotherapy treatment cycles, as well as an increase in the incidence of end-stage renal disease (dialysis), has increased demand for EPO. Side effects of EPO, such as arterial hypertension, iron deficiency, and influenza-like syndrome, as well as the longer duration of EPO treatment (4-6 weeks), limit the growth of the erythropoietin drugs market.

A full report of Wooden Decking Market is available at:https://orionmarketreports.com/global-epoetin-beta-erythropoietin-market/92816/  

Furthermore, rising commercialization trends for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and increased awareness of the benefits of EPO therapeutics all contribute to the growth of the erythropoietin drugs market.For instance, in May 2018, Pfizer Inc has announced that RETACRIT (epoetin alfa-epbx), an erythropoiesis-stimulating agent (ESA) biosimilar to Epogen and Procrit, has been approved by the FDA (epoetin alfa). RETACRIT is the first and only ESA approved in the US at the moment.

A number of industries, including several sub-domains of health care, have been forced to close due to the COVID-19 outbreak. Furthermore, there has been a significant impact and increase in demand for a variety of medical services, including erythropoietin. Erythropoietin (EPO), is a drug for anemia that can be effective against COVID-19, according to researchers at the Max Planck Institute of Experimental Medicine in Göttingen. When SARS-CoV-2 attacks the brain, they claim that the growth aspect of erythropoietin can prevent serious disease development and protect people from long-term neurological effects. Primary case studies show that erythropoietin is beneficial. A randomized clinical trial is currently being planned to systematically investigate the effects of using erythropoietin to treat COVID-19. It is a hormone that is primarily produced by the kidneys via hypoxia-inducible factor-2.

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape-Amgen Inc., Johnson & Johnson, Roche Group, Pfizer Inc., Novartis, Celltrion Inc., LG Life Sciences Ltd., among others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Epoetin Beta Erythropoietin Market Report by Segment

By Type

Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others

By Application

Anemia
Kidney Disorders
Other

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.